Isabel Mur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Isabel Mur has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Francesc Vidal
Universitat Rovira i Virgili, Tarragona, Spain
2 shared publications - Pere Domingo
Hospital de la Santa Creu i Sant Pau Barcelona Spain
2 shared publications - Ema Molas
From the Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
1 shared publication María Del Mar Gutierrez
Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
1 shared publicationMaría Gracia Mateo
Infectious Diseases Unit. Hospital De La Santa Creu I Sant Pau, Institut De Recerca Del Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
1 shared publicationNoemí Corbacho
From the Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Institut de Recerca del Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 26 February 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (9) , 1127-1141
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)
When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed.Data from observational...
- 26 February 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (9) , 1127-1141
Open AccessPharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)
When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed.Data from observational...
- 4 January 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (6) , 743-753
The pharmacological management of cardiovascular disease in people living with HIV (PLWH)
Summary Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment strategies are similar. However, there are CVR factors particular to PLWH, which need separate consideration. These factors are those HIV-dependent, those related to HIV-derived consequences, and combination antiretroviral therapy (cART)-dependent. Areas covered: In this review, the authors discuss the management of CVD in PLWH, with a special interest in pharmacological treatment and drug-drug interactions with cART. Expert opinion: In recent years, we have witnessed a decreased CVD morbidity and mortality in PLWH, which probably reflects an improvement in the management of CVR factors and CVD in these patients, partially thanks to new developments in antiretroviral therapy. Therefore, although there is still room for improvement, at present, the old desideratum of equalling PLWH and the general population in terms of CVD incidence and prognosis is a little closer.
- 4 January 2021
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (6) , 743-753
The pharmacological management of cardiovascular disease in people living with HIV (PLWH)
Summary Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment strategies are similar. However, there are CVR factors particular to PLWH, which need separate consideration. These factors are those HIV-dependent, those related to HIV-derived consequences, and combination antiretroviral therapy (cART)-dependent. Areas covered: In this review, the authors discuss the management of CVD in PLWH, with a special interest in pharmacological treatment and drug-drug interactions with cART. Expert opinion: In recent years, we have witnessed a decreased CVD morbidity and mortality in PLWH, which probably reflects an improvement in the management of CVR factors and CVD in these patients, partially thanks to new developments in antiretroviral therapy. Therefore, although there is still room for improvement, at present, the old desideratum of equalling PLWH and the general population in terms of CVD incidence and prognosis is a little closer.